Covid: Fewer stomach bugs recorded during UK's lockdown
Food poisoning and gastroenteritis cases plummeted in England, as people stayed at home. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - March 22, 2022 Category: Consumer Health News Source Type: news

Increasing usage of chlorhexidine in health care settings: blessing or curse? A narrative review of the risk of chlorhexidine resistance and the implications for infection prevention and control
This study reviewed the published data regarding the evidence of reduced CHG susceptibility, the cross-resistance with antibiotics, and the implications for infection control for S. aureus, coagulase-negative staphylococci, E. coli, K. pneumoniae, and P. aeruginosa. Despite incongruity in definitions of " resistance, " increased CHG minimal inhibitory values of these pathogens have been described, and different mutations encoding for CHG efflux pumps have been identified. Clinical relevance of species with reduced susceptibility to CHG is debatable and cross-resistance with antibiotics remains controversial. However, some ...
Source: Current Awareness Service for Health (CASH) - March 21, 2022 Category: Consumer Health News Source Type: news

The science is in: wearing shoes inside your home is just plain gross | Mark Patrick Taylor and Gabriel Filippelli for the Conversation
From lead to E Coli to endocrine-disrupting chemicals, the filth that clings to your soles is best left outside, environmental chemists sayYou probably clean your shoes if you step in something muddy or disgusting (please pick up after your dog!). But when you get home, do you always de-shoe at the door?Plenty of Australians don ’t. For many, what youdrag in on the bottom of your shoes is the last thing on the mind as one gets home.Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - March 17, 2022 Category: Science Authors: Mark Patrick Taylor and Gabriel Filippelli for the Conversation Tags: Hygiene Life and style Health Science Source Type: news

Literature review on the distribution characteristics and antimicrobial resistance of bacterial pathogens in neonatal sepsis
Purpose: Neonatal sepsis (NS) has no specific clinical manifestations and blood culture analysis requires a long period of time. Knowledge of prevalent bacterial isolates and their antibiotic susceptibility is crucial when choosing an empirical therapy to decrease morbidity and mortality. This literature review summarizes the distribution characteristics and antimicrobial resistance of bacterial pathogens associated with bloodstream infections in Chinese neonates, and thus serves as a reference for pediatricians. Methods: The full-text journal database, CNKI, was searched using the key words " neonatal " , " sepsis " , and...
Source: Current Awareness Service for Health (CASH) - March 14, 2022 Category: Consumer Health News Source Type: news

Bacteria Set Off Viral "Bombs" Inside Neighbors
A study finds some E. coli can deploy a chemical called colibactin to reawaken long-dormant viruses inside bacteria, causing destruction. (Source: The Scientist)
Source: The Scientist - March 7, 2022 Category: Science Tags: News & Opinion Source Type: news

What Causes Rectal Prolapse?
Discussion Rectal prolapse is defined as a herniation of the rectum through the anal verge. In children it is also usually mucosal prolapse and not full thickness. Partial or mucosal prolapse usually is seen as radial folds occurring 1 – 2.5 cm from the anal verge. Full thickness will protrude more than 5 cm. It affects genders equally and occurs most commonly in children under age 4. This is due to vertical course and low position of the anus, looser supporting tissues and less muscular support. These children are more likely to have prolapse but are less likely to have it recur. After age 4 the rectum takes the adu...
Source: PediatricEducation.org - February 28, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Health officials issue warning over an 'extremely antibiotic-resistant' bug mainly affecting gay men
The UK Health Security Agency (UKHSA) said there has been an increase in cases of Shigella sonnei, a gut infection that causes diarrhoea, stomach cramps and a fever. (Source: the Mail online | Health)
Source: the Mail online | Health - January 27, 2022 Category: Consumer Health News Source Type: news

A Newly Published Network Meta-Analysis (NMA) Found TREMFYA ® (guselkumab) Ranked Highest for Overall Level of Skin Clearance and Provided Positive Joint Efficacy Among Active Psoriatic Arthritis (PsA) Therapies
Conclusions (i.e., comparable) are based on an overlap of pairwise 95 percent credible intervals.1c. PASI 90 is defined as at least 90 percent improvement from baseline in the PASI score. The PASI score grades the amount of surface area on each body region that is covered by PsO plaques and the severity of plaques for their redness, thickness, and scaliness.13 PASI 90 was not a controlled endpoint in DISCOVER-1 or -2.8,9d. TREMFYA q4w dosing is not currently FDA-approved.2e. The PsA-modified vdH-S score combines erosion and joint space narrowing scores derived from radiographs of joints in body regions impacted by PsA.14 T...
Source: Johnson and Johnson - January 26, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

A Platform for Automated CRISPR-Based Microbial Genome Engineering
Discover how you can design and generate genomic edits to optimize heterologous protein expression and activity in E. coli. (Source: The Scientist)
Source: The Scientist - January 25, 2022 Category: Science Tags: The Marketplace Source Type: news

Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA)
Interim data submitted to the FDA show majority of pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walk within timeframes typical of healthy babies, as well as maintain swallowingEvrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to dateBasel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age w...
Source: Roche Media News - January 25, 2022 Category: Pharmaceuticals Source Type: news

Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)
Interim data submitted to the FDA show majority of pre-symptomatic babies treated withEvrysdi for at least one year were able to sit, stand and walk within timeframes typical of healthy babies, as well as maintain swallowingEvrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to dateBasel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age w...
Source: Roche Investor Update - January 25, 2022 Category: Pharmaceuticals Source Type: news

Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)
Basel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA). The sNDA submission incorporates interim data from the RAINBOWFISH study, which shows the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting, standing, walking and maintained the ability to swallow following 12 months of treatment.  “Treating very youn...
Source: Roche Media News - January 25, 2022 Category: Pharmaceuticals Source Type: news

Roche ’s Evrysdi (risdiplam) granted FDA priority review for treatment of pre-symptomatic babies under 2 months of age with spinal muscular atrophy (SMA)
Basel, 25 January 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has granted priority review of a supplemental new drug application (sNDA) for the use of Evrysdi® (risdiplam) to treat pre-symptomatic babies under two months of age with spinal muscular atrophy (SMA). The sNDA submission incorporates interim data from the RAINBOWFISH study, which shows the majority of pre-symptomatic babies treated with Evrysdi achieved key milestones such as sitting, standing, walking and maintained the ability to swallow following 12 months of treatment.  “Treating very youn...
Source: Roche Investor Update - January 25, 2022 Category: Pharmaceuticals Source Type: news

What Are Common Gastrointestinal Polyposes in Children?
Discussion Bloody stools or blood in the diaper is a relatively common complaint in general pediatrics. For most patients it is often a minor concern. Commonly it is a transient problem (e.g. rectal fissure caused by constipation or trauma) or often not blood (e.g. urate crystals in the diaper, food, menses, etc.). Real blood does occur with an identifiable cause such as long distance running or heavy exercise, or milk protein allergy/sensitivity that improves with a milk-restricted diet. Many more serious causes are associated with heavier or more recalcitrant bleeding, increased defecation, abdominal pain, poor eating an...
Source: PediatricEducation.org - January 24, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news

Fosfomycin Not Noninferior to Comparators for Bacteremic UTI
FRIDAY, Jan. 14, 2022 -- For patients with bacteremic urinary tract infections (bUTIs) due to multidrug-resistant (MDR) Escherichia coli, fosfomycin is not noninferior to comparators, with an increased rate of adverse event-related discontinuations,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 14, 2022 Category: Pharmaceuticals Source Type: news